Bruce Binkowitz

Corporate Officer/Principal bij ARCUTIS BIOTHERAPEUTICS, INC.

Health Technology

Consumer Services

Actieve functies van Bruce Binkowitz

Bedrijven	Functie	Begin	Einde
ARCUTIS BIOTHERAPEUTICS, INC.	Corporate Officer/Principal	23-08-2021	-

Bedrijven	Functie	Begin	Einde
Shionogi, Inc. Shionogi, Inc. Pharmaceuticals: MajorHealth Technology Part of Shionogi & Co., Ltd., Shionogi, Inc. is a pharmaceutical company based in Florham Park, NJ. Since 1878, the company has been utilizing science to address health challenges and has discovered several novel antibiotics and medications for HIV and influenza. Shionogi conducts ongoing research into established products and new antibiotic compounds, as well as developing an investigational antiviral for COVID-19. The company is committed to pursuing discovery through partnerships, including collaboration with scientists through investigator-initiated research. Shionogi is dedicated to advancing the greater good by developing, partnering, and commercializing medicine to treat serious unmet medical needs in infectious disease and other areas of high medical need including neurology and cardiovascular disease. Nathan McCutcheon has been the CEO of the company since 2019.	Corporate Officer/Principal	-	-

University of Florida	Graduate Degree
Rutgers School of Public Health	Doctorate Degree

Internationaal

Verenigde Staten

Operationeel

Corporate Officer/Principal	2
Graduate Degree	1
Doctorate Degree	1

Sectoraal

Health Technology	3
Consumer Services	3

Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Beursgenoteerde bedrijven	1
ARCUTIS BIOTHERAPEUTICS, INC.	Health Technology

Bedrijven in privébezit	1
Shionogi, Inc. Shionogi, Inc. Pharmaceuticals: MajorHealth Technology Part of Shionogi & Co., Ltd., Shionogi, Inc. is a pharmaceutical company based in Florham Park, NJ. Since 1878, the company has been utilizing science to address health challenges and has discovered several novel antibiotics and medications for HIV and influenza. Shionogi conducts ongoing research into established products and new antibiotic compounds, as well as developing an investigational antiviral for COVID-19. The company is committed to pursuing discovery through partnerships, including collaboration with scientists through investigator-initiated research. Shionogi is dedicated to advancing the greater good by developing, partnering, and commercializing medicine to treat serious unmet medical needs in infectious disease and other areas of high medical need including neurology and cardiovascular disease. Nathan McCutcheon has been the CEO of the company since 2019.	Health Technology

Bedrijven in privébezit

Health Technology